Knight Therapeutics Inc. provided revenue guidance for the fiscal year 2024. For the period, the company expected to generate revenues between $335 million to $350 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.1 CAD | +3.04% | +4.81% | +17.53% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.53% | 451M | |
+8.26% | 72.94B | |
-10.36% | 5.07B | |
+51.87% | 4.78B | |
+4.51% | 3.9B | |
-14.26% | 2.56B | |
+21.35% | 2.42B | |
-23.94% | 2.39B | |
+20.02% | 2.18B | |
+3.66% | 1.65B |
- Stock Market
- Equities
- GUD Stock
- News Knight Therapeutics Inc.
- Knight Therapeutics Inc. Provides Revenue Guidance for the Fiscal Year 2024